Moolec Science (MLECW) Net Cash Flow (2022 - 2024)
Moolec Science (MLECW) posted Net Cash Flow of -$21.0 million for Q4 2024, down 1114.91% sequentially from -$1.7 million in Q3 2024, and up 43.87% YoY from -$14.6 million in Q1 2024.
Moolec Science (MLECW) Net Cash Flow (2022 - 2024) Analysis & Trends
Moolec Science has reported Net Cash Flow for 3 years, with the latest figure at -$21.0 million in Q4 2024.
- Quarterly Net Cash Flow rose 43.87% year-over-year to -$21.0 million in Q4 2024, while the trailing twelve-month figure through Mar 2026 was -$21.0 million (changed N/A YoY) and the FY2025 annual result came in at -$47.4 million, down 544.19% from the prior year.
- Net Cash Flow slipped to -$21.0 million in Q4 2024 per MLECW's latest filing, from -$1.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $9.3 million in Q2 2024 and troughed at -$37.4 million in Q4 2023.
- A 3-year average of -$4.3 million and a median of -$274097.0 in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 4204.67% in 2023, down 17683.37% in 2023.
- Over 3 years, Net Cash Flow stood at $573367.0 in 2022, then tumbled by 6624.43% to -$37.4 million in 2023, then jumped by 43.87% to -$21.0 million in 2024.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$21.0 million, -$1.7 million, and $9.3 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -21.00 Mn |
| Dec 31, 2024 | -21.00 Mn |
| Sep 30, 2024 | -1.73 Mn |
| Sep 30, 2024 | -1.73 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Dec 31, 2023 | -37.41 Mn |
| Dec 31, 2023 | -37.41 Mn |
| Sep 30, 2023 | -1.70 Mn |
| Sep 30, 2023 | -1.70 Mn |
| Jun 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | 4.47 Mn |
| Mar 31, 2023 | -5.64 Mn |
| Mar 31, 2023 | -5.64 Mn |
| Dec 31, 2022 | 573,367.00 |
| Dec 31, 2022 | 573,367.00 |
| Sep 30, 2022 | 9,648.00 |
| Sep 30, 2022 | 9,648.00 |